Description
Baxter International: The Novum LVP Overhang Keeps 2026 Recovery Under Pressure!
Baxter International reported first quarter 2026 sales from continuing operations of $2.7 billion, marking a 3% increase on a reported basis but a 1% decline organically year-over-year. Adjusted earnings per share from continuing operations were $0.36, down 35% from the prior year’s $0.55, reflecting known headwinds including unfavorable expense timing, tariff impacts, higher manufacturing costs, and ongoing challenges related to the Novum large-volume pump (LVP) platform. The company reiterated its full-year 2026 guidance, anticipating flat to 1% reported sales growth, with organic sales expected to be roughly flat, and adjusted earnings per share in a range of $1.85 to $2.05. Segment performance was mixed. The Medical Products & Therapies segment (MPT) saw a 2% organic sales decline, notably a 5% decline in Infusion Therapies and Technologies driven by the Novum LVP shipment and installation hold, customer returns, and transitions to the Spectrum platform.
